Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
New York Genome Center | RCV001591655 | SCV001815674 | uncertain significance | Familial acute necrotizing encephalopathy | 2020-09-23 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV001591655 | SCV002306775 | uncertain significance | Familial acute necrotizing encephalopathy | 2020-11-26 | criteria provided, single submitter | clinical testing | In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. Algorithms developed to predict the effect of missense changes on protein structure and function (SIFT, PolyPhen-2, Align-GVGD) all suggest that this variant is likely to be disruptive, but these predictions have not been confirmed by published functional studies and their clinical significance is uncertain. This variant has not been reported in the literature in individuals with RANBP2-related conditions. This variant is present in population databases (rs762433464, ExAC 0.03%). This sequence change replaces proline with threonine at codon 2640 of the RANBP2 protein (p.Pro2640Thr). The proline residue is highly conserved and there is a small physicochemical difference between proline and threonine. |